Amarin Stock Jumps as Debate Moves to Heart Drug’s Potential Label

(Bloomberg) -- The unanimous panel backing to expand the label for Amarin Corp.’s heart drug Vascepa sparked debate across Wall Street as analysts and investors weighed whether the drug could be so...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.